CELU — Celularity Inc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1752828 ·
Last close
$0.63
Market Cap
$18.38M
52W High
$1.15
52W Low
$0.56
ADV30
103,940
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,104,000 | -3,270,000 | -22,058,000 | -24,362,000 | 107,329,000 | 6,175,000 | 145,391,000 |
| Sep 2025 | 5,284,000 | 1,380,000 | -12,900,000 | -23,076,000 | 114,239,000 | 120,000 | 134,333,000 |
| Jun 2025 | 5,736,000 | 494,000 | -15,864,000 | -24,524,000 | 120,283,000 | 863,000 | 145,780,000 |
| Mar 2025 | 11,426,000 | 7,872,000 | -10,486,000 | -19,754,000 | 128,876,000 | 293,000 | 134,382,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-13,257,000
Investing CF
$0
Financing CF
$18,649,000
CapEx
$-91,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-3.47
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-991,483,000
Inventory
$571,000
Receivables
$4,653,000
ST Investments
—
EBIT TTM
$-84,959,000
Pretax Income TTM
$-91,713,000
Interest Exp TTM
$6,754,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$26,550,000
EBITDA
$-54,013,000
Free Cash Flow
$5,384,625
Enterprise Value
$87,227,368
Total Cash
$6,175,000
Total Debt
$74,713,000
Shares Out
28,945,961
Trailing EPS
$-3.59
Book Value
$-1.32
ROE
—
ROA
-30.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 26,550,000 | -61,308,000 | -91,716,000 | 107,329,000 | 145,391,000 | — | -13,254,000 |
| Dec 2024 | 54,220,000 | -38,551,000 | -57,892,000 | 132,682,000 | 123,845,000 | — | -6,401,000 |
| Dec 2023 | 22,771,000 | -76,479,000 | -196,295,000 | 143,889,000 | 102,929,000 | — | -38,685,000 |
| Dec 2022 | 17,975,000 | -148,267,000 | 14,192,000 | 401,066,000 | 202,165,000 | — | -137,876,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.57
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DARE | Dare Bioscience, Inc. | $18.27M | $1.22 | — |
| QNTM | Quantum Biopharma Ltd. | $18.49M | $2.89 | — |
| VYNE | Yarrow Bioscience, Inc. | $18.60M | $27.85 | — |
| NCEL | NewcelX Ltd. | $18.79M | $3.49 | — |
| MRKR | Marker Therapeutics, Inc. | $18.84M | $1.13 | — |
News headlines (Yahoo Finance, 1h cache)
Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies
2026-06-04 12:00 · Yahoo
Celularity Releases CEO Letter to Shareholders
2026-06-03 20:15 · Yahoo
Celularity Appoints Rick Gonzalez as Chief Commercial Officer
2026-06-03 12:00 · Yahoo
Celularity Receives Nasdaq Notice Regarding Form 10-Q
2026-05-29 21:15 · Yahoo
NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors
2026-05-06 13:00 · Yahoo
Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation
2026-05-01 20:30 · Yahoo
NEXGEL Appoints Ian Blackman as Chief Financial Officer
2026-04-27 13:00 · Yahoo
NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment
2026-04-21 13:00 · Yahoo
Celularity Announces Closing of Transaction with NexGel
2026-04-21 12:30 · Yahoo
NEXGEL, Inc. Q4 2025 Earnings Call Summary
2026-04-21 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.